• J&J is making some new investments in microbiome research, including adding Caelus Health to its J&J Innovation portfolio. “These collaborations and investments will create critical new insights to address metabolic disorders through microbiome-based diagnostics and therapeutics,” said Dirk Gevers, PhD, Global Head, Janssen Human Microbiome Institute. “By partnering with entrepreneurs, biotechs and academics and bringing innovative opportunities together with our expertise, we look to move microbiome science forward and deliver future solutions that promote individual health.”
• London-based Arix Bioscience is looking to raise £100 million to invest in new biotech companies. Arix is planning a listing for the raise, looking to sell shares at 200 pence each. The firm has close ties with a range of top research centers in the UK.
• Mustang Bio, a subsidiary of Fortress Biotech $FBIO, says it has raised $94.5 million in a private placement, with plans to spend the cash on CAR-T development work. Their initial work is on brain cancer and acute myeloid leukemia. Not much has been reported about this company.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription